Domů › Akutní myeloidní leukemie › Florida › Miami
Klinické studie Akutní myeloidní leukemie v Miami, FL
24 studií pro Akutní myeloidní leukemie hledá účastníky v lokalitách v Miami a okolí (do cca 30 mil). Otevřete studii a zjistěte, kdo se může zapojit a jak kontaktovat tým studie.
Oficiální text studie (anglicky)
Hledáte účastníky pro studii? Zvýrazněte ji nahoře na této stránce – $99 na 30 dní →
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Probíhá náborFáze 2
- Miami Cancer Institute, Miami
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Probíhá náborFáze 2
- Miami Cancer Institute, Miami
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Probíhá náborFáze 2
- Miami Cancer Institute, Miami
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Probíhá náborFáze 2
- Miami Cancer Institute, Miami
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Probíhá náborFáze 2
- Miami Cancer Institute, Miami
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Probíhá náborFáze 3
- University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami
Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML
Probíhá náborFáze 2
- University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
Probíhá náborFáze 1
- University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Probíhá náborFáze 1/2
- Nicklaus Children's Hospital, Miami
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Probíhá náborFáze 3
- University of Miami, Miami
eHealth Mindfulness-based Music Therapy Intervention for Patients Undergoing Stem Cell Transplantation
Probíhá nábor
- University of Miami, Miami
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
Probíhá náborFáze 2/3
- Bioresearch Partners, Miami
Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents
Probíhá náborFáze 2
- University of Miami, Miami
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Probíhá náborObservační studie
- University of Miami (peds), Miami
- Niklaus Children's Hospital, Miami
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Probíhá náborFáze 2/3
- University of Miami - Sylvester Comprehensive Cancer Center, Miami
Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy
Probíhá náborFáze 2
- University of Miami, Miami
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Probíhá náborFáze 1/2
- University of Miami, Miami
- Miami Cancer Institute, Miami
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Probíhá náborFáze 2
- University of Miami, Miami
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Probíhá náborFáze 1
- University of Miami Health System, Miami
Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Probíhá náborFáze 1
- University of Miami, Miami
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
Probíhá náborFáze 1
- Sylvester Comprehensive Cancer Center, Miami
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Probíhá náborFáze 1/2
- University of Miami - Miller School of Medicine, Miami
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
Probíhá náborVítáni zdraví dobrovolníci
- University of Miami, Miami
APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML
Probíhá náborFáze 1
- University of Miami, Miami
Studie Akutní myeloidní leukemie v jiných městech
- Houston, TX85 studií
- New York City, NY51 studií
- Boston, MA44 studií
- Baldwin Park, CA40 studií
- Seattle, WA40 studií
- Columbus, OH35 studií
- Philadelphia, PA34 studií
- Durham, NC33 studií
- Atlanta, GA30 studií
- Tampa, FL29 studií
- Chicago, IL26 studií
- Portland, OR25 studií
Další studie v Miami
- Rakovina prsu42 studií
- Rakovina (všechny typy)36 studií
- Nemalobuněčný plicní karcinom31 studií
- Rakovina prostaty27 studií
- Obesity27 studií
- Metastatický karcinom24 studií
- Rakovina vaječníků23 studií
- Nadváha23 studií
- Mnohočetný myelom21 studií
- Ulcerózní kolitida21 studií
- Alzheimerova choroba20 studií
- Rakovina plic20 studií
Zdroj: ClinicalTrials.gov, data načtena 5. 10. 2026. Každá studie má vlastní kritéria způsobilosti; o účasti rozhoduje tým studie.